DK1879566T3 - Sammensætninger og fremgangsmåder til inhibering af mavesyresekretion - Google Patents

Sammensætninger og fremgangsmåder til inhibering af mavesyresekretion

Info

Publication number
DK1879566T3
DK1879566T3 DK05780180.5T DK05780180T DK1879566T3 DK 1879566 T3 DK1879566 T3 DK 1879566T3 DK 05780180 T DK05780180 T DK 05780180T DK 1879566 T3 DK1879566 T3 DK 1879566T3
Authority
DK
Denmark
Prior art keywords
inhibiting
procedures
compositions
sticky acid
accretion
Prior art date
Application number
DK05780180.5T
Other languages
English (en)
Inventor
Aleksey Kostadinov
Ayelet David
Sabina Glozman
Original Assignee
Vecta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1879566(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vecta Ltd filed Critical Vecta Ltd
Application granted granted Critical
Publication of DK1879566T3 publication Critical patent/DK1879566T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05780180.5T 2005-05-11 2005-07-28 Sammensætninger og fremgangsmåder til inhibering af mavesyresekretion DK1879566T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67966405P 2005-05-11 2005-05-11
PCT/IB2005/002223 WO2006120500A1 (en) 2005-05-11 2005-07-28 Compositions and methods for inhibiting gastric acid secretion

Publications (1)

Publication Number Publication Date
DK1879566T3 true DK1879566T3 (da) 2014-06-10

Family

ID=37396225

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05780180.5T DK1879566T3 (da) 2005-05-11 2005-07-28 Sammensætninger og fremgangsmåder til inhibering af mavesyresekretion

Country Status (16)

Country Link
US (2) US7803817B2 (da)
EP (1) EP1879566B1 (da)
JP (1) JP5161071B2 (da)
KR (2) KR101421994B1 (da)
CN (1) CN101184482B (da)
AU (1) AU2005331689B2 (da)
CA (1) CA2607803C (da)
DK (1) DK1879566T3 (da)
ES (1) ES2482771T3 (da)
HK (1) HK1120421A1 (da)
IL (1) IL187236A (da)
PL (1) PL1879566T3 (da)
RU (1) RU2385154C2 (da)
TW (1) TWI388316B (da)
WO (1) WO2006120500A1 (da)
ZA (1) ZA200709745B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
PL226695B1 (pl) * 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
SE0602446L (sv) * 2006-11-16 2008-05-17 Entress Ab Ny användning av kända farmakologiskt aktiva kemiska sammansättningar
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
KR20150003908A (ko) * 2007-07-03 2015-01-09 다누타 크루셰프스카 유기 바이오연료의 제조를 위한 알파­케토글루타레이트의 용도
CN102014638A (zh) * 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
AU2008343787B2 (en) * 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
ES2370790B2 (es) * 2010-05-25 2012-10-18 Universidade De Santiago De Compostela Uso de oxalacetato en el tratamiento de isquemia.
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CN103442727B (zh) 2011-02-11 2016-08-10 Zx制药有限责任公司 多微粒l-薄荷醇制剂及相关方法
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
RS58325B1 (sr) 2013-04-23 2019-03-29 Zx Pharma Llc Enterosolventno obloženi višečestični preparat sa proteinskom sub-oblogom
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
MX2021007095A (es) 2018-12-20 2021-08-11 Colgate Palmolive Co Composicion de cuidado bucal que comprende zinc y un aminoacido para tratar los sintomas de un trastorno gastrico en la cavidad bucal.
CN114315750B (zh) * 2020-09-29 2024-05-10 鲁南制药集团股份有限公司 一种莫沙必利-丁二酸共晶

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2343011A (en) 1941-07-11 1944-02-29 Huppert Oskar Thio-protein plastic
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS59104326A (ja) 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPS60193917A (ja) 1984-03-14 1985-10-02 R P Shiila- Kk 多重構造軟カプセル剤
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB8621425D0 (en) 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
IL88507A (en) 1987-12-03 1993-02-21 Smithkline Beckman Intercredit 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
JP2656338B2 (ja) 1989-01-31 1997-09-24 日東電工株式会社 口腔粘膜貼付製剤
CA2015981A1 (en) 1989-05-10 1990-11-10 Thomas H. Brown Compounds
US5048353A (en) 1990-03-01 1991-09-17 Beloit Corporation Method and apparatus for roll profile measurement
JPH03287103A (ja) 1990-04-02 1991-12-17 Seiko Epson Corp カラーフィルターの形成法
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
CA2083606C (en) 1990-06-20 2001-08-21 Arne Elof Brandstrom Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use
JPH06510547A (ja) 1992-07-06 1994-11-24 コミスサローバ，イリナ　アレクセエフナ 抗アルコール活性を有し、エネルギー代謝と胃粘膜の酸を生成し分泌する機能とを刺激し、放射能防御活性と抗コレラ活性を有する医薬組成物
US7795239B2 (en) 1992-07-27 2010-09-14 Mueller Medical International LLC Saccharide compositions and method of use
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
DE69530989T2 (de) 1994-08-13 2004-05-19 Yuhan Corp. Neue pyrimidinderivate und verfahren zu ihrer herstellung
ES2094694B1 (es) 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US5677302A (en) 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
US6296876B1 (en) 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
EE04576B1 (et) * 1997-12-08 2006-02-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Suposiit happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod, toimeaineühik ja selle valmistamismeetod ning preparaat
IT1296980B1 (it) 1997-12-17 1999-08-03 Istituto Pirri S R L Capsula doppia come forma farmaceutica per la somministrazione di principi attivi in terapie multiple
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
DE69916273T2 (de) 1998-06-18 2005-05-19 Vecta Ltd. Verwendung von gastrin fragmenten oder sythetischen analogen von gastrin zur herstellung eines arzneimittels zur behandlung der helicobacter pylori assozierten störungen
SE9902386D0 (sv) 1999-06-22 1999-06-22 Astra Ab New formulation
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US7365047B1 (en) 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
WO2002086504A2 (en) 2001-04-24 2002-10-31 Mcgill University Individualization of therapy with gastroesophageal reflux disease agents
US6298876B1 (en) * 2001-05-02 2001-10-09 Ozone Industries, Inc. Quick disconnect coupling
US20030235628A1 (en) 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
US20030175360A1 (en) 2002-02-22 2003-09-18 Renzo Luzzatti Symptomatic relief of gastrointestinal disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
NZ536267A (en) 2002-04-10 2007-06-29 Fred H Miller Multi-phase, multi-compartment and multi-ingredient capsular system
ATE536887T1 (de) 2002-06-06 2011-12-15 Univ Washington Kovalente konjugate zwischen mit artemisinin verwandten endoperoxiden und eisentragenden proteinen und anwendungsverfahren
EP1562439B1 (en) 2002-09-24 2016-04-13 Gumlink A/S Chewing gum comprising at least two different biodegradable polymers
WO2005020879A2 (en) * 2003-08-27 2005-03-10 Vecta Ltd. Compositions for treating pathologies that necessitate suppression of gastric acid secretion
US20060135406A1 (en) * 2002-10-14 2006-06-22 Sabina Glozman Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion
IL152289A0 (en) * 2002-10-14 2003-05-29 Vectabiotics Ltd Method and composition for inhibiting h.pylori infection in a mammalian tissue
JP2006510731A (ja) 2002-10-24 2006-03-30 マイカップ ピーエルシー 標的化送達
GB2394895A (en) 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
JP2006518751A (ja) 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
CA2529984C (en) * 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
EP1660052A2 (en) 2003-09-03 2006-05-31 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
AU2005204014B2 (en) 2004-01-06 2008-02-28 Panacea Biotec Ltd. Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
US20050181052A1 (en) 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
JP2007532677A (ja) 2004-04-16 2007-11-15 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤、および運動促進薬の組み合わせ
AU2005294382A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
EP2801354B1 (en) 2004-10-08 2017-02-08 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
US7918908B2 (en) 2008-04-30 2011-04-05 Venturedyne, Ltd. Dust collector with equalized cleaning performance

Also Published As

Publication number Publication date
CA2607803C (en) 2013-12-17
KR101447909B1 (ko) 2014-10-08
US7803817B2 (en) 2010-09-28
US20100247634A1 (en) 2010-09-30
TW200714278A (en) 2007-04-16
HK1120421A1 (en) 2009-04-03
IL187236A (en) 2016-07-31
ZA200709745B (en) 2008-11-26
EP1879566B1 (en) 2014-03-12
IL187236A0 (en) 2008-06-05
EP1879566A4 (en) 2009-04-15
KR101421994B1 (ko) 2014-07-22
JP2009502740A (ja) 2009-01-29
JP5161071B2 (ja) 2013-03-13
WO2006120500A1 (en) 2006-11-16
US20060257467A1 (en) 2006-11-16
KR20080005566A (ko) 2008-01-14
CA2607803A1 (en) 2006-11-16
RU2007140941A (ru) 2009-06-20
US9278080B2 (en) 2016-03-08
EP1879566A1 (en) 2008-01-23
RU2385154C2 (ru) 2010-03-27
KR20120051097A (ko) 2012-05-21
CN101184482B (zh) 2012-02-01
PL1879566T3 (pl) 2015-01-30
TWI388316B (zh) 2013-03-11
AU2005331689A1 (en) 2006-11-16
AU2005331689B2 (en) 2011-05-19
ES2482771T3 (es) 2014-08-04
CN101184482A (zh) 2008-05-21

Similar Documents

Publication Publication Date Title
DK1879566T3 (da) Sammensætninger og fremgangsmåder til inhibering af mavesyresekretion
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK3081215T3 (da) Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin
DK1969007T3 (da) Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK3308788T3 (da) Sammensætninger og fremgangsmåder til modulering af smn2-splejsning
DK3851447T3 (da) Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
DK1858864T3 (da) Stabiliserede sammensætninger af flygtige alkyleringsmidler og fremgangsmåder til anvendelse deraf
DK2653873T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK1991678T4 (da) Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
DK2679245T3 (da) Formuleringer, der stabiliserer og hæmmer udfældning af immunogene sammensætninger
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
ITMI20062368A1 (it) Composizioni erbicide
DK1858342T3 (da) Fremgangsmåde til fremstilling af ernæringssammensætninger
DK2170403T3 (da) Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener
SMP200900058B (it) Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
DK3085386T3 (da) Fremgangsmåde til hæmning af knogleresorption
DK3354276T3 (da) Sammensætninger til behandlingen af gastrointestinal inflammation
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
SMAP200900020A (it) Composti e composizioni come inibitori di proteinachinasi
DE602007011453D1 (de) Ladungszurückhaltungsschaltung zur zeitmessung
DK2041071T3 (da) Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK2089047T3 (da) Sammensætninger og fremgangsmåder til beskyttelse og regenerering af hjerte-væv